These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 8930195)

  • 1. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
    Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
    Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic effect related to the plasma concentration of pentisomide in vivo and the antiarrhythmic-concentration relationship in vitro.
    Hachisu M; Chen H; Soneda T; Fujishima K; Ishizuka T; Konno F
    Drugs Exp Clin Res; 1995; 21(4):145-51. PubMed ID: 8529527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high plasma prostaglandin to thromboxane ratio protects against renal ischemia.
    Kaufman RP; Anner H; Kobzik L; Valeri CR; Shepro D; Hechtman HB
    Surg Gynecol Obstet; 1987 Nov; 165(5):404-9. PubMed ID: 3672299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
    Komori S; Sawanobori T; Tamura K; Kane KA; Parratt JR
    Jpn J Pharmacol; 1994 Jul; 65(3):193-200. PubMed ID: 7799519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
    Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
    J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of OKY-046, a selective thromboxane A2 synthetase inhibitor, on ventricular arrhythmias and prostaglandins during coronary artery ligation and reperfusion in anesthetized dogs.
    Ogura T; Watanabe I; Saito T; Saito S; Ozawa Y; Hatano M
    Jpn J Pharmacol; 1988 May; 47(1):95-8. PubMed ID: 3411822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
    Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
    Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combined use of prostaglandin I2 analogue (OP-2507) and thromboxane A2 synthetase inhibitor (OKY-046) strongly inhibits atherosclerosis of aortic allografts in rats.
    Hirano T; Nakafusa Y; Kawano R; Motoyama K; Arima T; Sugitani A; Tanaka M
    Surgery; 2001 May; 129(5):595-605. PubMed ID: 11331452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic, hemodynamic and cardiac electrophysiological evaluation of N-(2,6-dimethylphenyl)-N'-[3-(1-methylethylamino)propyl]urea (Wy-42,362).
    Bergey JL; Sulkowski T; Much DR; Wendt RL
    Arzneimittelforschung; 1983; 33(9):1258-68. PubMed ID: 6685506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of quercetin on platelet and reperfusion-induced arrhythmias in rats.
    Xiao D; Gu ZL; Qian ZN
    Zhongguo Yao Li Xue Bao; 1993 Nov; 14(6):505-8. PubMed ID: 8010047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of R- and S-enantiomers of Ro 22-9194, (2R)-2-amino-N- (2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate and (2S)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide L-tartrate, in dog heart preparations.
    Murakami M; Furukawa Y; Karasawa Y; Ren LM; Takei M; Narita M; Chiba S
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):165-71. PubMed ID: 1383626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory effects of mercaptoalkylguanidines on cyclo-oxygenase activity.
    Zingarelli B; Southan GJ; Gilad E; O'Connor M; Salzman AL; Szabó C
    Br J Pharmacol; 1997 Feb; 120(3):357-66. PubMed ID: 9031736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats.
    Manning AS; Bruyninckx C; Ramboux J; Chatelain P
    J Cardiovasc Pharmacol; 1995 Sep; 26(3):453-61. PubMed ID: 8583788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
    J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
    Ogletree ML; Harris DN; Heran CL; Phillips MB; Michel IM; Goldenberg HJ
    Eicosanoids; 1988; 1(2):85-91. PubMed ID: 2856188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.